Healthcare Equipment and Supplies
Company Overview of SynCardia Systems, Inc.
SynCardia Systems, Inc. manufactures artificial hearts. Its permanent replacement heart is used as a bridge to transplant for patients suffering from end-stage heart failure affecting both sides of their heart (biventricular failure). The company was formerly known as Syn-Cor Systems, Inc. The company was founded in 2001 and is based in Tucson, Arizona.
1992 East Silverlake Road
Tucson, AZ 85713
Founded in 2001
Key Executives for SynCardia Systems, Inc.
Chief Executive Officer, President and Director
Co-Founder, Chairman of Science Advisory Board, Chief Scientific & Medical Officer and Director
Vice President of Communications
Chief Development Officer
Compensation as of Fiscal Year 2015.
SynCardia Systems, Inc. Key Developments
SynCardia Systems, Inc. Receives FDA Approval to Conduct an Investigational Device Exemption Clinical Study on the Effective Use of 50cc SynCardia Temporary Total Artificial Heart
Mar 31 15
SynCardia Systems, Inc. has received FDA approval to conduct an Investigational Device Exemption (IDE) clinical study on the effective use of its 50cc SynCardia temporary Total Artificial Heart. The FDA approval will allow SynCardia to launch the study with as many as 30 heart failure patients. Patients enrolled in this study will receive the 50cc SynCardia Total Artificial Heart as a bridge to a donor heart transplant. Under the study, the 50cc SynCardia Total Artificial Heart initially will be available for implantation in - 10 pediatric patients 10-18 years old - 10 adult patients 19-75 years old - 10 patients who would not otherwise qualify under the study criteria. This secondary arm is expected to further characterize the use of the 50cc SynCardia Heart. All patients in the study must be eligible for donor heart transplant. As part of the study and to better understand the patient populations that can benefit from the 50cc SynCardia Heart, images of the patients' chest cavities will undergo 3D modeling. Study data through the first six months of patient use will be provided to the FDA as part of its review and approval process. Patients will be followed for up to two years to report on their experiences.
Dan Hudspeth Joins SynCardia Systems, Inc. as Chief Financial Officer
Feb 24 15
Dan Hudspeth has been named Chief Financial Officer of SynCardia Systems, Inc. Hudspeth has an extensive background in financing, accounting, manufacturing and distribution within high-growth private equity-based and public companies. A certified public accountant inactive, Hudspeth most recently provided interim executive and board advisory services to venture capital and private equity-backed companies though his company, Cohesive Strategy LLC.
SynCardia Systems, Inc. Presents at 27th Annual ROTH Conference, Mar-10-2015 02:30 PM
Feb 13 15
SynCardia Systems, Inc. Presents at 27th Annual ROTH Conference, Mar-10-2015 02:30 PM. Venue: The Ritz Carlton, 1 Ritz Carlton Dr, Dana Point, CA 92629, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
September 15, 2014
Most Searched Private Companies
Sponsored Financial Commentaries